Chairperson's Welcome

John Crison
VP Pharmaceutical Products
MEDIVAS,LLC

Develop a "Value-Creation" Strategy for Your Successful Specialty Pharma Business Model

Moderator:
Michael Step, SVP Corporate Development, SANTARUS

Panelists:
John Crison, VP Pharmaceutical Products, MEDIVAS,LLC
David Socks, VP Business Development, CADENCE PHARMACEUTICALS
John Kapoor, President, EJ FINANCIAL, Founder, FIRST HORIZON / SCIELE PHARMA

Learn the Process of How to Find the Right Drugs for Your Business

Alex Tkachenko, Vice President, BD and Operations Planning, HANA BIOSCIENCES

DURECT-NYCOMED Collaboration: A Case Study in Regional Deal Making to Enable and Enhance Your Specialty Pharma Strategy

Michael H. Arenberg, Executive Director of Business Development, DURECT CORPORATION

Networking & Refreshment Break

Getting the Funds You Need to Build and Grow Your Company

Moderator:
Glen Sato, Partner, Life Sciences, COOLEY GODWARD KRONISH

Panelists:
Camille Samuels, Managing Partner, VERSANT VENTURES
Nikhil Puri, Managing Director, BEAR, STEARNS & CO, INC
Jonathan Norris, Managing Director, Private Equity Group, SVB CAPITAL
Todd Davis,Managing Director, COWEN HEALTHCARE ROYALTY PARTNERS

Networking Luncheon

How to Prepare for an Exit Strategy: Evaluating Your Options

Panelists:
Zsolt Lavotha, President & Chief Executive Officer, OREXO
James Gale, Managing Director, SANDERS MORRIS HARRIS
Philip L. Smith, General Partner, SR ONE LIMITED

So You've Gone Public…Now What?

Zsolt Lavotha, President & Chief Executive Officer, OREXO

Uncover the Top 10 Most Critical Steps in Building a Marketing & Sales Force

Peter Stein, Chief Executive Officer, NORGINE

Product vs. Pipeline: How to Increase Your Chances of Drug Delivery Success

Brian Gorin, Managing Principal, ANALYSIS GROUP

Who Should Attend the Pharma Workshop:
CEOs and senior-level management from specialty pharmaceutical companies, investment bankers, specialty pharmaceutical market analysts and venture capitalists.

By Attending This Symposium You Learn How To:

• Use your resources more efficiently for development and growth
• Acquire the funds you need for expanded commercialization
• Develop an effective marketing and sales force within your category
• Assess the driving factors of adopting a successful specialty pharma model

Workshop Leader:

Paul Karl Horan, President, PRESCRIPTIVE KINETICS

Sue Slezak, OSCIENT PHARMACEUTICALS

Part One: So You Have a Drug Delivery Technology…How Do You Get a Deal?

When looking to partner, a series of internal processes must be completed in order to define your objectives in partnering, to profile the unmet needs your technology addresses and to identify and rank the likely partners for your technology...

Part Two: Now that you have a Potential Partner….How do You Establish Value and Translate it to Contract Terms?

The art of valuation is a subjective assessment of worth depending on the proposed utility of a technology or product to a potential "buyer" and some base estimates of the "seller"....

Part Three: Case Study Negotiation

Workshop participants are divided into teams to apply the knowledge gained through the previous sessions...

Who Should Attend this Workshop:
Senior-level management at pharmaceutical, biotechnology and drug delivery companies within:

• Licensing/Technology Transfer
• Business/Corporate Development
• Deal Valuation
• Strategic Planning
• Legal Affairs
• Portfolio Management

By Attending This Symposium You Learn How To:

• The homework you need to complete in-house before attempting to partner
• How to attract the best partners?
• How to market your drug delivery technology?
• Who should draft a term sheet and when? Who should draft the final agreement?
• Valuation methods and how to perform them-an overview of the methods commonly used to value drug delivery technologies and companies and the pros and cons of each
• How to incorporate the elements of a deal that are important to each party?
• The difference between "value" and "value-added" assessment and which is most appropriate based on
  the strengths of your technology
• How to translate valuation assessments into contract components to create "win-win" deals
• Where the proposed working relationship can impact deal value and milestone payments-sharing the risks
  and sharing the rewards

Welcome & Introduction

Peter Hoffman, PhD, VP New Technology Development, GENZYME PHARMACEUTICALS

Understanding the Challenges in Formulation Parameters, Manufacturing Process Options, and Dosage Presentations Involved in Bringing New Protein-Based Therapeutics and Vaccines to Market

Vu L. Truong, PhD, Vice President & CSO, ARIDIS PHARMACEUTICALS

IMPROVING ANTIGEN DELIVERY: Single-shot vaccine development

Marc Kirchmeier, Associate Director, MERCK RESEARCH LABORATORIES

Protein Drug Delivery: An Update from the Langer Laboratory

Daniel S. Kohane MD, PhD, HARVARD MEDICAL SCHOOL

Design for Peptide Delivery: Part One & Two Part One: Optimizing Peptide Structure for Delivery

Part Two: Design for Peptide Delivery: Advantages of Optimizing Peptides for Delivery

Torsten Woehr, PhD, Associate Director, Commercial Development, GENZYME PHARMACEUTICALS
Thomas R. Tice, PhD, Executive Vice President and Chief Scientific Officer, BROOKWOOD PHARMACEUTICALS, INC

High Concentration Monoclonal Antibody Formulations

Larry Brown, ScD, Chief Technology Officer, EPIC THERAPEUTICS, INC, a wholly owned subsidiary of Baxter

Non-Invasive Transdermal Delivery of Proteins & Peptides

Eric Tomlinson PhD DSc, President and Chief Executive Officer, ALTEA THERAPEUTICS

Enhancing Intranasal Delivery of Peptide Therapeutics

Richard L. Mitchell, PhD, Scientific Director, Marketing & Business Development, NASTECH PHARMACEUTICAL COMPANY INC

Using the Lungs as a Portal for Protein and Peptide Delivery

Jeffry Weers, PhD, Senior Director of Drug Development, NEKTAR THERAPEUTICS

Oral Delivery…Will We Ever Reach the Holy Grail?

Peter Hoffman, PhD, VP New Technology Development, GENZYME PHARMACEUTICALS

Who Should Attend this Workshop:

• Formulation Development
• Protein Engineering/Chemistry
• Peptide Engineering/Chemistry
• Integration of Advanced Devices
• Analytical Development
• Pharmaceutical Sciences
• Quality Control
• Stability
• Targeted Delivery
• Controlled Delivery
• Biomaterials Science
• Drug Discovery Science

Workshop Leader:

Akan Oton, Global Marketing Director , CARDINAL HEALTH

John W. Draper, Vice President, Strategic Planning and Managed Markets, CARDINAL HEALTH

Jack Wright, PharmD, Vice President, Business Development, CARDINAL HEALTH

• What is driving the escalating outcomes expectations of patients, physicians and payors?
• Review of key principles - outcomes, medication adherence, patient compliance - what do they mean, how measured, etc
• What role does advanced formulation technology play in helping improve outcomes
• How can dose form choice impact perceived and actual patient compliance and/or outcomes?
• Selected therapeutic class outcome and compliance pattern review

Who Should Attend:
Drug delivery professionals within

• Business Development
• Licensing
• Research & Development